Peggy Fung, GSK’s Vice President and Head of Vaccine Business in China, has opted to leave the UK pharmaceutical giant. Her departure is slated for August 9, 2024. Fung, an alumna of the Chinese University of Hong Kong, previously led the South China business for Merck Serono. In 2009, she joined Pfizer, a major player in the U.S. pharmaceutical industry, where she held several key positions, including EPBU Head, Hong Kong and Macau Regional Marketing Director, and Head of Pfizer Malaysia.
Fung assumed leadership roles at GSK in September 2019 as General Manager for GSK Greater China and the Intercontinental Region, including Hong Kong and Macau. In June 2021, she transitioned to oversee GSK’s vaccine business in China. Following a January 2024 restructuring of GSK China’s business into three core departments—specialty drugs, vaccines, and respiratory—Fung continued to head the vaccine division.- Flcube.com
